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Abstract
Objectives: The population of individuals with substance use (SUD) and/or psychiatric disorders (PD) has a high
prevalence of smoking and a consequent increase in tobacco-related morbidity and mortality when compared to the
general population. The aim of this study is to examine the outcomes of a program in a real-life setting which takes a
tailored approach to smoking cessation among individuals with SUD and/or PD.
Methods: A retrospective chart review of tailored tobacco dependence treatment was performed on individuals with
histories of SUD and/or PD attending a Tobacco Dependence Clinic (TDC) program in Vancouver, British Columbia,
Canada. Participants of the TDC received a combination of behavioural counselling and pharmacotherapy for smoking
cessation. Data from 540 participants enrolled in the TDC between September 2007 and May 2011 was reviewed.
Outcome measures included seven-day point-prevalence abstinence (validated by expired carbon monoxide) and
program completion rates.
Results: For individuals who completed the program the abstinence rate was 41.1% (167/406). Significant
predictors of successful smoking cessation were: a) a lower expired carbon monoxide level at baseline (OR=.98,
95%CI=.96-1.00), and b) a longer duration of treatment (OR=1.09, 95%CI=1.05-1.12). Significant predictors of program
completion were: a) being female (OR=1.86, 95%CI=1.21-2.87).
Discussion: Tailored smoking cessation among individuals with SUD and/or PD yields modest end-of-treatment
smoking cessation rates and can be an effective approach to reducing the burden of tobacco use in substance use and
mental health treatment settings.

Keywords: Smoking cessation (SC); Substance use disorders (SUD);
Psychiatric disorders (PD); Tailored interventions

Tobacco use remains the number one preventable cause of
morbidity and mortality in Canada [1]. Based on the Canadian
Tobacco Use Monitoring Survey (CTUMS), at present smoking rates
for Canadians aged 15 years and older is 18%, representing about
4.9 million smokers [2]. Although there has been a steady decline
in the overall smoking prevalence in Canada during the last decade
[3], some subsets of the population continue to smoke at high rates,
particularly individuals with a history of substance use disorders
(SUD) and/or psychiatric disorders (PD). Studies suggest that these
individuals often have disproportionately higher mortality than the
general U.S. population [4] - mortality which is often smoking related
[5]. In the U.S., studies have estimated smoking rates of up to four
times the national average among clinical populations with SUD
and PD [6-8]. Although there are no estimates for smoking among
individuals with PD in Canada as a whole, a recent survey among
individuals with severe and persistent mental illness accessed through
Community Mental Health Centres in Western Canada reported a
smoking prevalence of 46.8% [9]. This high prevalence of smoking
among individuals with SUD and PD clearly warrants a need for
targetted efforts to reduce the disease burden and increased mortality
risk among these often disparate sub-populations.
Fortunately, individuals with SUD and PD are often willing
to engage in smoking cessation treatment with some measure of
success. A survey among participants in a methadone maintenance
treatment program found that 80% of smokers expressed an interest
(i.e., responded: ‘somewhat’ or ‘very’ interested) in quitting smoking
[10]. In a more recent review of nine studies assessing the motivation
to quit smoking among individuals with PD, over 50% of smokers in
this population contemplated quitting smoking in the next 60 days
[11]. Moreover, previous studies have demonstrated that smoking
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cessation interventions among individuals with co-occurring SUD’s
may result in improved health outcomes [12] and drug abstinence [1316]. A meta-analysis of nineteen studies addressing smoking cessation
interventions among individuals in addictions treatment and recovery
found that such interventions resulted in increased smoking cessation
at 12 week (although non-significant at 6-month follow-up) and a 25%
likelihood of long-term abstinence from alcohol and illicit drugs [17].
These findings were corroborated by a recent review of the literature
which found that smoking cessation interventions do not impair
cessation from other substances of abuse and may actually enhance
the success of substance abuse treatment [18]. Thus, with the current
state of evidence, smoking cessation is not only contemplated but
can result in improved health (and other substance abuse) outcomes
among individuals with SUD and/or PD.
The purpose of this study is to report smoking cessation outcomes
from a program with an innovative, tailored approach to smoking
cessation among individuals with SUD and/or PD histories accessing
outpatient addiction services [19]. Since its inception in September
2007, the Tobacco Dependence Clinic (TDC) has provided services to
over 700 tobacco dependent individuals with a history of SUD and/or
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PD. The specific aims of this study are to examine:
a) Smoking cessation outcomes at end-of-treatment
b) Smoking cessation outcomes by histories of SUD, PD, or both
c) Predictors of successful smoking cessation
d) Predictors of successful program completion.

Methods

dependence than the general population. The medications are
dispensed weekly after each group session during a brief consultation
with the TDC nurse or physician. Each visit is charted, including
type of medication dispensed and expired CO monitoring (where
appropriate). Program completers are defined as those who complete
at least 6 weeks of the 8-week structured program (allowing for two
missed sessions). Non-completers are those who engaged for less than
6 weeks before disengaging or dropping out from the program.

Setting and participants

Measures

The TDC provides smoking cessation treatment under the
auspices of Vancouver Coastal Health (VCH) Mental Health and
Addiction Services. Eligibility to participate in the TDC is based upon
4 main criteria:1) 19 years or older, 2) tobacco dependent, 3) history
of a substance use disorder and/or a mental illness, and 4) financially
disadvantaged (i.e., individuals who had no source of income and/
or were on disability and/or demonstrated that their primary source
of income is based on governmental assistance). Intake assessment
includes obtaining of a medical, psychiatric, and previous tobacco
use and treatment history, and vital signs and expired carbon
monoxide (CO) monitoring. Participants also sign a consent form
for information from their charts to be used for an ongoing program
evaluation of the TDC. Currently, the TDC has seven operating sites
at VCH Community Health Centres in Vancouver, BC.

Baseline sociodemographic data included sex (male vs. female)
and age (in years). In addition, a smoking history obtained at the
participants’ initial visit to the program included age at smoking
initiation, number of cigarettes smoked per day (cigs per day), and
importance and confidence in quitting smoking (both on a scale of 0
to 10) [21,22]. Moreover, information on substance use (categorized
as: none, alcohol, opiates, cocaine, marijuana, methamphetamine
and related drugs) and psychiatric disorder (categorized as: none,
mood disorder, anxiety disorder, psychotic disorder) histories were
obtained. The psychiatric disorder history was assessed primarily
by patient history and review of current and/or past medications.
Finally, data was obtained from participant charts on the type of
pharmacotherapy received during treatment (i.e., monotherapy vs.
combination therapy), Fagerstrom Test for Nicotine Dependence
(FTND) scores at beginning of treatment [23,24], weekly expired
carbon monoxide (CO) levels measured in parts per million (ppm)
[25], and total number of weeks in treatment.

Treatment approach and program completion
Current evidence-based guidelines recommend combining
behavioural therapies with pharmacotherapy for optimal tobacco
dependence treatment outcomes [20]. In keeping with these
guidelines, the TDC program provides behavioural counselling
with no-cost pharmacotherapy. The TDC program approach further
assumes that smoking cessation is a process and not an event; as such,
no set ‘quit date’ is emphasized in the program. Rather, behavioural
counselling is provided during 8, weekly, “structured” group sessions
of 1.5 hours duration followed immediately by a further optional 18,
weekly, “support” group sessions of 1 hour duration. The behavioural
counseling sessions aim to enhance motivation and self-efficacy to
quit smoking as well as to foster skills for relapse prevention and
maintaining abstinence. Group sessions are based on a manual that
is standardized between clinics and facilitated by a drug and alcohol
counselor (see supplemental materials). Non-attendance at group is
followed up by a supportive telephone call by a nurse/counsellor.
Moreover, the novelty of the TDC program approach to tobacco
dependence treatment is that pharmacotherapy is tailored to the
participants’ need in terms of dose, duration of treatment, and
potentially combining multiple smoking cessation medications.
Unlike many traditional smoking cessation programs which provide
pharmacotherapy for durations of 8 to 12 weeks, the TDC program
employs, the principle of “titrating to effect” in which participants
are offered nicotine replacement therapy (i.e., nicotine patch, gum,
lozenge, and inhaler) and/or oral medications (i.e., bupropion and
varenicline) at higher doses and for longer durations (up to 26 weeks)
to optimize participants efforts in smoking cessation. This approach to
pharmacotherapy is in recognition that traditional smoking cessation
programs often use conservative pharmacotherapy approaches which
may, in effect, ‘under dose’ participants, particularly individuals with
SUD and/or PD which smoke at higher rates and have higher nicotine
J Addict Res Ther
ISSN:2155-6105 JART an open access journal

Data analysis
Retrospective data from participants’ charts were extracted by
two research assistants for those enrolled in the seven TDC sites from
September 2007 to May 2011.The characteristics of the sample were
described using frequencies and means (M) with standard deviations
(SD). Differences between program completers and non-completers
for all study variables were analyzed using chi-square (with degrees
of freedom=DF) for categorical and ordered categorical variables and
independent sample t-tests (with Levine’s test for equality of variance)
for all continuous variables. Of the 739 individuals that engaged with
the TDC in the specified time frame, 196 (26.5%) had 2 or less contacts
with the program (including intake assessment and orientation to the
program) and were deemed insufficiently engaged in the program. We
compared baseline characteristics between those who remained in the
program and those who had 2 or less contacts and found that there
were no differences in the sex (χ2=0.07, DF=1, p=.785) or self-disclosed
diagnosis of a psychiatric disorder (χ2=0.67, DF=3, p=.879); however,
individuals who did not engage in the program were younger in age
(45.1yrs vs. 48.0yrs, p=.003), had lower mean nicotine dependence
scores (5.7 vs. 6.1, p=.040) and had on average lower expired CO
levels at baseline (18.3ppm vs. 20.7ppm, p=.027). Furthermore, 3
individuals described their gender as ‘other’ than male or female and
where excluded from further analysis. Thus the analysis is based on
540 individuals.
The primary outcome measure was smoking status at end-oftreatment. End-of-treatment was defined as completing the 8-week
structured group and stopping treatment (in consultation and
agreement with program providers) any time within the additional
nine to eighteen weeks of support group therapy. Successful smoking
cessation was defined using seven-day point-prevalence of smoking
abstinence (i.e., not smoking in the past 7 days, based on participant
Volume 2 • Issue 4 • 1000115
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self-report with biochemical validation of expired CO≤8ppm when
available). If an expired CO level was not recorded on the participant’s
chart at the end-of-treatment, we used a next-observation-carriedbackward (NOCB) or last-observation-carried-forward (LOCF)
method [26], from the weekly expired CO record, validated by
participants self-report of no cigarette use in the preceding week to
determine abstinence. If there was no record in the chart regarding
smoking status or available expired CO, the participant was considered
still smoking and a treatment failure (n=60). Counting such
missing records as failures is an approach which will conservatively
underestimate (but not inflate) the effects of the treatment.
The secondary outcomes were to examine smoking cessation by
SUD and PD history, by length of stay in the program, and to assess
predictors of successful smoking cessation and program completion.
We employed chi-square analyses to examine smoking cessation by

histories of SUD, PD, and co-occurring disorders (i.e., none vs. SUD
only vs. PD only vs. both SUD and PD) and by length of stay in the
program. To assess predictors of smoking cessation and program
completion, we employed a two-step model building procedure [27].
In the first step, crude odds ratios (reported in Odds Ratio=OR,
and 95% Confidence Intervals=95%CI) were used to determine the
associations between smoking cessation and all study variables. In
the second step, only variables associated with smoking cessation
(alpha ≤.10) were included in the final multivariate analyses using
adjusted odds ratios. In assessing predictors of smoking cessation, the
final logistic regression analysis was further stratified by gender to
determine disaggregated differences in smoking cessation outcomes
among women and men. The Hosmer-Lemeshow test was employed
to assess global goodness-of-fit. For analyses, a p-value of .05 or lower
was used to determine statistical significance. All analyses were
performed using PASW statistics version 18.0.

Total
(N = 540)
n

Completersb
(n = 406)
%

Non-completersc
(n = 134)
%

n

n

%

Gender

Difference**
χ2 (df), p
9.53 (1), .002

Female

210

38.9

173

42.6

37

27.6

Male

330

61.1

233

57.4

97

72.4

None

65

12.0

51

12.6

14

10.4
40.3

Primary Substance Use History

5.20 (5), .393

Alcohol

183

33.9

129

31.8

54

Opiates*

64

11.9

51

12.6

13

9.7

Cocaine

140

25.9

105

25.9

35

26.1

Marijuana

63

11.7

52

12.8

11

8.2

Methamphetamine and related drugs

25

4.6

18

4.4

7

5.2

None

125

23.1

88

21.7

37

27.6

Primary Mental Health Diagnosisa

3.36 (3), .339

Mood disorder

301

55.7

227

55.9

74

55.2

Anxiety disorder

77

14.3

63

15.5

14

10.4

Psychotic disorder

37

6.9

28

6.9

9

6.7

Monotherapy

141

26.9

103

25.6

38

31.1

Combination therapy

383

73.1

300

74.4

84

68.9

Pharmacotherapyd

1.45 (1), .228

Mean

SD

Mean

SD

Mean

SD

t (df), p

Age of participant (years)

48.1

11.0

48.3

11.0

47.4

10.9

.833 (536), .405

Age at smoking initiation

14.8

4.9

14.9

5.0

14.5

4.7

.739 (532), .460

Importance of quitting

9.0

1.3

9.0

1.3

9.0

1.4

.286 (520), .775

Confidence in quitting

7.3

2.2

7.3

2.3

7.4

2.1

.330 (515), .741

Cigarettes smoked per day

21.0

10.3

21.1

10.6

20.6

9.5

.469 (538), .639

FTNDf at baseline

6.1

2.1

6.1

2.1

6.1

2.0

.325 (532), .746

CO level at baseline

20.7

12.5

20.6

12.1

21.2

13.5

.482 (520), .630

a. The ‘mood disorder’ category includes primarily individuals with depression and bipolar disorder. The ‘anxiety disorder’ category includes individuals primarily with
generalized anxiety disorder, posttraumatic stress disorder, and panic disorders. The ‘psychotic disorder’ category includes individuals with a primary past history of schizophrenia, schizoaffective disorder, psychotic disorder.
b. Program completers are individuals who had at least 6 contacts with the Tobacco Dependence Clinic program. The typical program involves 8 weeks (8 contact points) of
a closed group therapy session. Individuals could miss no more than two weeks (two contacts) to still have meaningful participation in the program. Of program completers,
8.4% (n =17) had 6 or 7 contacts with the program.
c. Program non-completers are individuals who had engaged in the program for more than two weeks, but had a total of less than 6 contact points (i.e., less than 6 weeks
in the program).
d. Pharmacotherapy represents the form of treatment (i.e., monotherapy vs. combination therapy) in the first month of treatment.
e. mean differences between completers and non-completers is expected as, by definition, non-completers did not have more than 6 weeks (6 contacts) with the program.
f. FTND = Fagerstrom Test for Nicotine Dependence. This is a six-item questionnaire of nicotine dependence, scored on a scale of ‘0’ (low) and ‘10’ (high).
* opiates (i.e., oxycontin, codeine, methadone, heroin)
** differences between groups was based on chi-square analysis for categorical variables and independent sample t-tests for continuous variables.
Table 1: Sample Characteristics.
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Results
Sample characteristics
The participants were mostly male (61.1%) with a mean age of 48.1
(SD=11.0) years. The most prevalent SUD and PD were alcohol use
disorders (33.9%) and mood disorders (55.7%), respectively, and 68%
of the sample had co-occurring SUD and PD. Approximately 75.2% of
participants completed the program, with significantly more females
completing the program compared to males. On average, program
completers (n=406) attended the TDC for 14.6 weeks (SD=6.8)
whereas non-completers (n=134) attended for 4 weeks (SD=0.8). There
were no other differences in baseline characteristics between program
completers and non-completers (Table 1).

Smoking cessation at end-of-treatment
Among program completers, 41.1% (167/406) achieved abstinence
by end-of-treatment. There was a significant likelihood of smoking
cessation with increased length of stay in treatment (χ2=26.2,
DF=4, p< .0001, see figure 1). A greater proportion of men achieve
smoking cessation as compared to women (42.1% vs. 39.9%) albeit this
difference was non-significant (p = .660).

Smoking cessation by history of SUD and/or PD
There were no significant differences in smoking cessation
between different diagnostic groups for those with histories of a SUD
(χ2=3.44, DF=5, p=.633) or a PD (χ2=3.88, DF=3, p=.274, see figure 2).
When the participants were categorized by history of co-occurring
psychiatric and substance use disorder, we found these individuals
were less likely to achieve smoking cessation than those with no
disorder, a SUD only, or a PD only (no disorder=43.8% vs. SUD
only=46.7% vs. PD only=45.7% vs. co-occurring=38.9%), however,
the differences between groups were non-significant.

Figure 2: End-of-treatment smoking cessation rates by psychiatric disorder
and substance use history among program completers (n = 406).

cessation at the end-of-treatment (Table 2). However, when the data
was disaggregated by sex, in the adjusted multivariate analysis among
both women and men only having lower CO levels at baseline and
longer treatment duration significantly predicted smoking cessation
at the end-of-treatment.

Predictors of successful program completion
In the first-step of the model building process, being female
(OR=1.95, 95%CI=1.27-2.98) and having an anxiety disorder (relative
to no psychiatric disorder) (OR=1.03, 95%CI=1.00-1.05) remained
predictive of program completion at alpha < 1.0. However in the
adjusted model only being female remained predictive of program
completion. [n=540, Hosmer-Lemeshow goodness-of-fit: χ2=2.87
(DF=4), p=.579].

Predictors of smoking cessation

Conclusions

Among the total sample of program completers, in the unadjusted
logistic regression analyses of the first-step in the model building
process, psychiatric disorder history (particularly anxiety disorder),
use of monotherapy in the first 4 weeks of treatment, lower nicotine
dependence scores, lower expired CO levels at baseline, and higher
total number of visits to the TDC were associated with smoking
cessation at alpha ≤ 1.0. However, in the adjusted multivariate analyses,
having an anxiety disorder (as compared to no psychiatric disorder)
lower FTND scores and expired CO levels at baseline, and having
longer treatment duration were significant predictors of smoking

This study presents the smoking cessation and program
completion outcomes of individuals with a history of SUD and/or
PD in an outpatient treatment setting. Moreover, these findings are
an update of the findings from a pilot study of outcomes from the
TDC [19]. Similar to the earlier pilot study, end-of-treatment smoking
cessation outcomes were 41.1% among program completers. These
end-of-treatment findings are comparable to those reported by
similar tailored approaches to smoking cessation among individuals
with SUD and/or PD. For example, among 231 male cigarette smokers
enrolled in a Veterans Affairs Mental Health Clinic Smoking Cessation
Program, Gershon Grand et al. [28] reported end-of-treatment
outcomes of 36.4%. Also, in a recent examination of a tailored
smoking cessation program among individuals with psychiatric
disorders, Selby et al. [26] reported seven-day point-prevalence quit
rates of 20.6% at end-of-treatment. Moreover, the pooled results of
18 studies of smoking cessation interventions among individuals in
addictions treatment and recovery reported smoking cessation rates
of 20.5% among participants in the treatment groups vs. 8.6% among
participants in the control groups at end-of-treatment (RR = 1.82, 95%
CI = 1.45-2.29); [17] however, these studies did not specifically provide
tailored smoking cessation interventions.

9-12 wks

13-16 wks

17-20 wks

21-26 wks

Figure 1: Smoking cessation by length of time in the program among program
completers (n = 406, χ2 = 26.2, df = 4, p < .0001).
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In our current study, although individuals with histories of alcohol,
opiates, and/or marijuana use and a history of co-occurring SUD and
PD were less likely to achieve smoking cessation compared to those
without such histories, the difference was not statistically significant.
In a pilot study we had found that individuals with alcohol, opiate
Volume 2 • Issue 4 • 1000115
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Total Sampled
Odds Ratio

Womend
95%CI

Odds Ratio

Mend
95%CI

Odds Ratio

95%CI

Primary Mental Health Diagnosisa
None (reference)

1.00

-

1.00

-

1.00

-

Mood disorder

.78

.45-1.35

1.75

.61-5.03

.54

.27-1.07

Anxiety disorder

.45*

.22-.94

.86

.25-2.93

.37

.13-1.05

Psychotic disorder

.89

.35-2.25

2.54

.56-11.60

.62

.17-2.25

Pharmacotherapy
Monotherapy

1.00

-

-

-

-

-

Combination Therapy

.66

.40-.109

-

-

-

.99-1.29

Confidence in quitting

-

-

-

-

1.13

FTNDc at baseline

.88*

.70-1.00

-

-

.93

.80-1.09

COc level at baseline (ppm)

.98**

.96-1.00

.97*

.94-1.00

.97*

.94-1.00

1.09***

1.05-1.12

1.07**

1.02-1.13

1.08***

1.04-1.13

Total number of visitsc to the TDC

The ‘mood disorder’ category includes primarily individuals with depression and bipolar disorder. The ‘anxiety disorder’ category includes individuals primarily with generalized anxiety disorder, posttraumatic stress disorder, and panic disorders. The ‘psychotic disorder’ category includes individuals with a primary past history of schizophrenia,
schizoaffective disorder, psychotic disorder.
b
Program completers are individuals who had at least 6 contacts with the Tobacco Dependence Clinic program. The typical program involves 8 weeks (8 contact points) of
a closed group therapy session. Individuals could miss no more than two weeks (two contacts) to still have meaningful participation in the program.
c
FTND = Fagerstrom Test for Nicotine Dependence. This is a six-item questionnaire of nicotine dependence, scored on a scale of ‘0’ (low) and ‘10’ (high). CO = Expired
Carbon monoxide. This is measured in parts per millimeter (ppm).
For FTND, CO level at baseline, and Total number of visits, the odds ratios represent the odds of smoking cessation per each unit increase in the variable.
d
Hosmer-Lemeshow goodness-of-fit results for Total sample (n= 388): χ2= 8.02 (DF=8), p=.432; for Women (n = 167): χ2= 7.30 (DF=8), p=.505; and for Men (n = 218):
χ2= 14.00 (DF=8), p=.082
*p <.05, **= p<.01, *** = p <.001
a

Table 2: Adjusted predictors of smoking cessation for 26 weeks for program completersb by gender.

and marijuana use were significantly less likely to achieve cessation
as compared to those without an SUD [19]. The non-significant
findings in our current study may be a reflection of the more rigorous
tailoring of medications, in terms of using combination therapy with
participants of the TDC. At least in theory, tailored approaches, when
appropriately delivered should not produce differences in outcomes
between diagnostic groups as has been observed in a previous study
[26]. However, our assumptions can only be speculative at best given
the observational nature of our current study.
However, we found that lower expired CO levels at baseline
and a longer duration of treatment remained significant predictors
of successful smoking cessation. This finding is also supported by
previous studies using such tailored approaches [26]. Moreover, our
present findings further suggest that, on average, the benefit of length
of treatment peaks at between 4 to 5 months (i.e., 16 to 20 weeks)
duration. Therefore, when considering the optimal duration of tailored
smoking cessation programming among individuals with SUD and/
or PD, our findings would suggest longer-term pharmacotherapy
and counselling support beyond the traditional 8-12 week treatment
models.
In addition, we found that although there are no significant
differences between men and women in terms of smoking cessation
outcomes, women are twice as likely to complete the program when
compared to men. Few studies have examined gender differences in
program completion for smoking cessation programs in addictions
treatment settings. A previous study found sex-disaggregated
differences in predictors of program completion among men and
women in a Health Management Organization (HMO) -based
substance abuse program [29]. In the study, predictors of program
completion among women included higher income and legal/agency
referral, whereas older age predicted completion among men [29].
Although our current study did not obtain demographic measures
J Addict Res Ther
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other than sex and age of participants, we did find that older age was a
predictor of program completion, and specifically among men.
We had anticipated that using combinations of pharmacotherapy
would have been an important significant predictor of abstinence
due to recent evidence-based recommendations [30]. Surprisingly,
when we compared those who were given some form of combination
therapy (i.e., combination NRT and/or NRT with oral medications)
with those who were given only a monotherapy (i.e., either a single
NRT product or a single oral medication), we found that those
given the combination therapy were less likely to achieve cessation
compared to those given monotherapy, albeit, the difference was
not significant in the multivariate analysis. As this study is not a
controlled trial, it is challenging to know the reasons why we obtained
such findings. However, future controlled trials may be required to
assess the effectiveness of combination therapy over monotherapy
among individuals with SUD and/or PD.
One limitation of this study relates to the verification of smoking
abstinence based on expired CO monitoring. Counted as treatment
failures were 11% (i.e. 60/540) of participants without available expired
CO levels at the end-of-treatment. Hence, the smoking cessation rates
at end-of-treatment may be an underestimate. A second limitation is
the retrospective design of the study which may introduce incomplete
study groups and interpretive bias during the chart review. Moreover,
because it is an observational study, no random assignment of
participants to treatment groups was performed. A third limitation
is that due to the transient nature of the population accessing the
TDC services, follow-up beyond end-of-treatment was challenging,
although several attempts were made. Without such follow-up data, we
cannot determine the long-term effectiveness of these tailored smoking
cessation outcomes. A fourth limitation is that beyond gender and
age, no other socio-demographic variables (i.e., income, education)
were obtained from the participants. However, all participants had
to meet the criteria of being financially disadvantaged in order to
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Citation: Khara M, Okoli CTC (2011) Smoking Cessation Outcomes among Individuals with Substance Use and/or Psychiatric Disorders. J Addict
Res Ther 2:115. doi:10.4172/2155-6105.1000115

Page 6 of 6
participate in the TDC program. Despite the inherent limitations in
the design of the study, we believe this study is an important addition
to the literature examining the effectiveness of tailored approaches to
smoking cessation among individuals with SUD and/or PD in reallife treatment settings.
In summary, the findings of our study provide some evidence
to suggest that an intensive, tailored approach to smoking cessation
among individuals with SUD and/or PD’s can yield modest end-oftreatment quit rates. Such an approach can yield high retention rates
among participants, partly because it reduces barriers to smoking
cessation by providing pharmacotherapy and counselling services at
no-cost. Future studies may determine the benefits of combination
therapy over monotherapy in this population, in addition to
determining the long-term effect of such interventions. Such studies
will be important to provide practice and policy directions in terms
of the provision of smoking cessation in addictions and mental health
treatment settings.
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